1. 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). (April 2015) Authors: Garcia-Manero, G.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Azarnia, N.; Petrone, M.E.; Snyder, B.R.; Maniar, M. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY. Issue 1 (April 2015) Authors: Steensma, D.; Abedi, M.; Bejar, R.; Cogle, C.; Foucar, K.; Garcia-Manero, G.; George, T.; Grinblatt, D.; Komrokji, R.; Maciejewski, J.; Pollyea, D.; Roboz, G.; Savona, M.; Scott, B.; Sekeres, M.; Thompson, M.; Sugrue, M.; Swern, A.; Nifenecker, M.; Erba, H. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 320 RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM. Issue 1 (April 2015) Authors: Komrokii, R.; Zeidan, A.; Al Ali, N.; Padron, E.; Lancet, J.; Steensma, D.; Dezern, A.; Roboz, G.; Jabbour, E.; Sekeres, M.; Garcia-Manero, G.; List, A. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?. (April 2015) Authors: Silverman, L.R.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Navada, S.C.; Azarnia, N.; Garcia-Manero, G. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC). (April 2017) Authors: Nazha, A.; Sekeres, M.; Komrokji, R.; Steensma, D.; Kantarjian, H.; Roboz, G.; Fenaux, P.; Prebet, T.; Azarnia, N.; Zbyszewski, P.; Fruchtman, S.; Santini, V.; Silverman, L.; Platzbecker, U.; Garcia-Manero, G. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL. (23rd June 2022) Authors: Jain, N.; Roboz, G.; Konopleva, M.; Liu, H.; Schiller, G.; Jabbour, E.; Desai, P.; Whitfield, D.; Haider, A.; Zernovak, O.; Frattini, M.; Brownstein, C.; Larson, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML. (23rd June 2022) Authors: Daver, N. G.; Montesinos, P.; Aribi, A.; Martinelli, G.; Altman, J.; Roboz, G.; Wang, E. S.; Burke, P. W.; Jeyakumar, D.; Walter, R. B.; DeAngelo, D. J.; Erba, H. P.; Advani, A.; Gastaud, L.; Thomas, X.; Todisco, E.; Pemmaraju, N.; Mendez, L.; de la Fuente, A.; Gaidano, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT). (23rd June 2022) Authors: Erba, H.; Pollyea, D.; Sekeres, M.; Garcia-Manero, G.; Seiter, K.; DeGutis, I.; Kiselev, P.; McBride, A.; Yu, E.; Roboz, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS). (September 2021) Authors: Kuendgen, A.; Nomdedeu, M.; Tuechler, H.; Garcia-Manero, G.; Komrokji, R.; Sekeres, M.; Della Porta, M.; Cazzola, M.; Malcovati, L.; Dezern, A.; Roboz, G.; Steensma, D.; Haase, D.; Stauder, R.; Cedena, M.T.; Van De Loosdrecht, A.; Schlenk, R.; Blum, S.; Grau, J.; Calvo, X. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS). (May 2023) Authors: Kuendgen, A.; Nomdedeu, M.; Tuechler, H.; Garcia-Manero, G.; Komrokji, R.; Sekeres, M.; Della Porta, M.; Cazzola, M.; Dezern, A.; Roboz, G.; Steensma, D.; Van De Loosdrecht, A.; Malcovati, L.; Schlenk, R.; Grau, J.; Calvo, X.; Blum, S.; Pereira, A.; Valent, P.; Costa, D. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗